Engineering T cells for cancer therapy
2005
Engineering T Cells for Cancer Therapy
publication
Evidence: moderate
Author Information
Author(s): Mansoor W, Gilham D E, Thistlethwaite F C, Hawkins R E
Primary Institution: Cancer Research UK, Department of Medical Oncology, University of Manchester
Hypothesis
Can engineered T cells effectively target and eliminate cancer cells?
Conclusion
Engineered T cells show promise in targeting cancer, but technical challenges remain.
Supporting Evidence
- Engineered T cells can be generated rapidly using retroviral gene transfer technology.
- Clinical responses have been documented in melanoma patients treated with engineered T cells.
- Adoptive T-cell therapy has shown effectiveness in treating hematological malignancies.
Takeaway
Scientists are trying to make special T cells that can find and kill cancer cells better. This could help treat cancer more effectively.
Methodology
The review discusses various gene therapy approaches for developing adoptive T-cell-based cancer treatments.
Limitations
The production of natural tumor-specific T cells is technically challenging and currently limited.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website